# VERACYTE, INC. stock analysis

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test

## Market evidence and data freshness

The public preview recorded VERACYTE, INC. at 46.08 USD on 2026-09-29T20:00:00.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-10-01 through 2026-08-07 across 1217 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## What should I review before buying VERACYTE, INC. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then your monthly usage limit. Access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/vcyt)